Biotech companies at BIO‑Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
121 biotech companies are at BIO-Europe 2026 — 72 presentations on the program. Most represented: Miltenyi Biomedicine (3 on the program), Atrogi (2 on the program), Genmab (2 on the program). 9 of them have their own page in this guide. As of Sep 29, 2026.
Track
Top represented
Showing 1–17 of 121 organizations
| Organization | BIO-Europe 2026 Attendance |
|---|---|
Miltenyi Biomedicine Bergisch Gladbach, Germany | |
Clinical-stage company of the Miltenyi Group developing CAR-T and other cell therapies for cancer and autoimmune disease. | Panel Tue Nov 10 10:00–10:45 Accelerating Access to Innovative Therapies for European Patients Through Integrated Decision-Making How approval, benefit reviews and pricing decisions could run side by side instead of one after another, so European patients get new medicines sooner. Panel Tue Nov 10 09:30–09:55 From Clinical Success to Commercial Readiness: Strategic Lessons in Bringing Advanced Therapies to Patients Lessons from preparing cell and gene therapies for launch by planning manufacturing, approval and reimbursement alongside the clinical trials. Talk Wed Nov 11 09:30–09:55 Bridging Therapeutic Areas: Navigating the Oncology–Autoimmune Convergence in Cellular Therapies What changes when cell therapies first developed for cancer move into autoimmune disease, from acceptable safety risks and trial endpoints to manufacturing. |
A Atrogi Stockholm, Sweden | |
Develops oral small molecules for type 2 diabetes and obesity that increase glucose uptake in skeletal muscle. | Panel Tue Nov 10 16:00–16:45 AI and Innovation in Clinical Trials: Transforming Operations and Accelerating Development How AI can speed clinical trials, from drafting trial plans and finding patients to computer-simulated patients that cut how many real ones are needed. Panel Tue Nov 10 10:00–10:45 Cardiometabolic innovations beyond GLP-1 – Where are we now? Which drug approaches beyond GLP-1 medicines are drawing attention for obesity, diabetes and heart disease risk, and where money and partnerships are going. |
Genmab Copenhagen, Denmark | |
Danish biotech developing antibody therapeutics for cancer and other diseases. | Panel Mon Nov 9 13:00–14:00 Navigating partnering and business development in a shifting global landscape How funding conditions, treatment trends and geopolitics are shaping partnerships and acquisitions between drug and biotech companies, with real deal examples. Panel Tue Nov 10 10:45–11:15 From Partnering Pioneer to Global Biotech Leader: The Next Chapter for European Innovation How Genmab grew from licensing its discoveries to others into a global company selling its own drugs, and what European biotechs can learn. |
Stanford spinout using AI-driven target and drug discovery around extrachromosomal circular DNA in cancer, with a European hub in Berlin. | Panel Tue Nov 10 09:30–09:55 Biopharma Ecosystem Germany: Spotlight on Innovation Drivers Ready for Take-Off Five teams from Germany's biotech scene, which spans university research, companies, drug manufacturing and healthcare, show their work and its impact. Panel Tue Nov 10 15:00–15:25 Inside the Incubator: What It Really Takes to Build a Biotech Company Today What incubators backed by big drug companies look for in young biotechs, and how they help founders with money, advice and partners. |
CellNBetter Daejeon, South Korea | |
Panel Tue Nov 10 14:00–14:30 Korea's Next Wave: Biotech Innovators to Watch Korean biotechs present work spanning drug formulation, safety testing, the microbiome, mRNA and gene therapy delivery, and engineered toxins for cosmetic use. | |
Genrix Biopharmaceutical Chongqing, China | |
Listed Chinese antibody drug company developing and marketing monoclonal, bispecific and multispecific antibodies. | |
Tubulis Munich, Germany | |
Develops antibody-drug conjugates for solid tumors using proprietary conjugation technologies. | Talk Mon Nov 9 09:00–10:00 Building Your BD Career: What Really Moves the Needle What it takes to build a career in drug licensing and partnership deals, from scientific and financial skills to credibility and contacts. Keynote Mon Nov 9 12:00–12:45 Building a competitive and impactful European biotech community: Perspectives from the European Life Sciences Coalition and CEOs How Europe can keep biotech talent, money and companies at home by drawing in big investors, speeding regulation and building stronger stock markets. Ecosystem InnovationBusiness of Biotech Panel Mon Nov 9 15:00–15:25 |
CT Cellula Therapeutics Epalinges, Switzerland | |
Swiss cell therapy biotech spun out of the University of Geneva. | Panel Wed Nov 11 10:30–10:55 Building a Clinical Strategy for First-in-Class Therapeutics How bold phase 3 trial designs, such as adaptive trials that change as data arrive, can help a first-of-its-kind rare disease drug succeed. Panel Wed Nov 11 11:00–11:45 Mission-Driven Investments: Balancing Capital and Clinical Impact Funding barriers that hold back clinical trials, ways to cut their costs, and investments that weigh patient benefit alongside financial return. |
Biocytogen Beijing, China | ◆Gold Sponsor |
Offers humanized mouse models, preclinical services and fully human antibody discovery, and licenses antibody assets including bispecifics and ADCs. | Talk Tue Nov 10 09:00–09:25 RenSuper Workstation: An AI-Driven Antibody Discovery Platform From Target to Antibody Leads in Click How Biocytogen combines immunized mice, DNA sequencing, AI screening and lab tests to find fully human antibody candidates in months, not years. |
AB AAVantgarde Bio Milan, Italy | |
Develops dual-AAV gene therapies for inherited retinal diseases such as Usher syndrome and Stargardt disease. | Panel Wed Nov 11 10:00–10:45 Envisioning the future of ophthalmology What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise. |
Ability Biotherapeutics Montreal, Canada | |
Develops conditionally activated and multispecific antibodies for cancer and autoimmune diseases, using a generative AI discovery platform. | Talk Mon Nov 9 09:00–10:00 Building Your BD Career: What Really Moves the Needle What it takes to build a career in drug licensing and partnership deals, from scientific and financial skills to credibility and contacts. |
Aerska Dublin, Ireland | |
Develops RNAi medicines for neurodegenerative diseases, using antibody shuttles to carry them across the blood-brain barrier. | Panel Tue Nov 10 09:00–09:45 Networks or neurons: What’s next in CNS dealmaking? What is driving recent deals between biotechs and larger drug companies for brain and nervous system drugs, which remain hard to develop. |
AT Agomab Therapeutics Ghent, Belgium | |
Develops organ-restricted small molecules for fibrotic diseases, including fibrostenosing Crohn's disease and idiopathic pulmonary fibrosis. | Panel Mon Nov 9 14:00–14:45 Voices from the IPO Class of ’25/’26: What’s Next? Leaders of biotechs that listed on the stock market in 2025 and 2026 describe life after going public and the hurdles they face. |
AP Alkeus Pharmaceuticals Cambridge, Massachusetts | |
Develops gildeuretinol, a deuterated vitamin A, for Stargardt disease and other retinal diseases. | Panel Tue Nov 10 09:45–10:45 China’s Clinical Revolution: From Regional Player to Global Innovation Engine Why global drug companies license more drugs from Chinese biotechs, and how China's fast trials and changing rules can speed worldwide development. |
AT ALTx Therapeutics | |
Francis Crick Institute spin-out developing cancer therapies that target the Alternative Lengthening of Telomeres pathway. | Panel Tue Nov 10 13:00–13:45 Building Biotech Companies, Not Just Funding Them How investors now build biotechs from scratch around university science, supplying leaders and shared resources, and whether that can be made repeatable. |
AT Amicus Therapeutics Princeton, New Jersey | |
Develops and markets therapies for rare diseases, including Fabry disease and Pompe disease. | Panel Wed Nov 11 11:30–12:00 What is the Future of Real-World Evidence (RWE) in Europe? How European regulators can use data from routine patient care, given uneven national rules and new EU-wide data-sharing projects. |
A AviadoBio London, United Kingdom | |
Develops gene therapies for neurodegenerative diseases, including frontotemporal dementia and ALS. | Panel Tue Nov 10 10:00–11:00 Manufacturing Next-Gen Therapeutics from Advanced Therapy Manufacturing to Novel Modalities How to cut the cost of making cell and gene therapies and mRNA medicines, and scale up without losing quality or patient access. |
Instantly find 20 buyers from biotech companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse BIO-Europe 2026 by
Organization type
Track
Everyone
Not affiliated with or endorsed by EBD Group, Informa Connect or BIO-Europe. Submit a correction